object
analysi
epidemiolog
risk
factor
outcom
viral
infect
children
adolesc
hematopoiet
cell
transplant
hct
method
multicent
nationwid
studi
total
hct
procedur
allohct
autohct
period
year
analyz
result
period
episod
viral
infect
diagnos
patient
incid
viral
infect
allohct
autohct
patient
frequent
infect
allohct
caus
cytomegaloviru
cmv
polyoma
bk
viru
bkv
epsteinbarr
viru
ebv
major
infect
occur
within
first
month
allohct
requir
pharmacotherapi
symptomat
therapi
median
time
treatment
specif
viral
infect
rang
ebv
cmv
day
highest
mortal
observ
case
cmv
infect
risk
factor
viral
infect
allohct
acut
leukemia
acut
chronic
graft
versu
host
diseas
acgvhd
match
unrel
donor
mud
mismatch
unrel
donor
mmud
hct
risk
factor
death
viral
infect
cmvigg
seroposit
acut
lymphoblast
leukemia
recipi
mudmmudhct
incid
ebv
infect
requir
preemptiv
treatment
rituximab
allohct
children
case
ebv
infect
episod
preced
viral
infect
treat
antivir
prevent
develop
ebvdnaemia
need
rituximab
treatment
case
case
gvhd
factor
enabl
develop
signific
ebvdnaemia
antivir
therapi
infect
conclus
shown
antivir
drug
prevent
ebv
reactiv
allohct
pediatr
patient
infect
major
caus
mobil
mortal
children
undergo
hematopoiet
cell
transplant
hct
chemotherapi
due
malign
accord
center
intern
blood
marrow
transplant
research
cibmtr
infecti
complic
caus
death
autolog
hct
autohct
match
sibl
donor
hct
msdhct
match
unrel
donor
hct
mudhct
recipi
infecti
complic
children
hct
note
children
allogen
hct
allohct
children
solid
tumor
lymphoma
pediatr
autohct
set
incid
viral
infect
allohct
observ
patient
first
day
transplant
day
day
year
hct
autohct
set
viral
infect
observ
patient
median
onset
day
posttranspl
virus
caus
infect
hct
classifi
latent
episod
natur
latter
acquir
typic
exposur
rather
result
reactiv
event
earli
posttranspl
period
herp
simplex
viru
hsv
reactiv
frequent
viral
infect
allohct
autohct
patient
overal
allohct
patient
die
primarili
due
infect
infect
viral
autohct
patient
death
due
infect
episod
major
improv
outcom
associ
applic
drug
molecular
test
detect
prevent
earli
bacteri
infect
hsv
cytomegaloviru
cmv
preengraft
candid
infect
screen
reactiv
preemptiv
treatment
applic
prophylaxi
seroposit
recipi
play
role
prevent
diseas
caus
latent
herpesvirus
cmv
human
herpesviru
varicellazost
viru
vzv
implement
diagnost
therapeut
strategi
manag
epsteinbarr
viru
ebv
infect
basi
monitor
ebvdnaemia
preemptiv
target
therapi
rituximab
reduc
incid
mortal
posttranspl
lymphoprolif
diseas
ebvptld
year
ganciclovir
gcv
reduc
ebv
replic
neither
ganciclovirfoscarnet
fcv
cidofovir
cdv
therapyprophylaxi
impact
develop
ebvptld
antivir
agent
recommend
multicent
nationwid
studi
present
analysi
epidemiolog
risk
factor
outcom
viral
infect
children
adolesc
hct
period
consecut
month
special
attent
given
antivir
drug
usag
incid
ebv
infect
hct
studi
design
multicent
nationwid
cohort
analysi
perform
behalf
polish
societi
pediatr
oncolog
hematolog
viral
infect
diagnos
sixyear
period
januari
decemb
report
polish
pediatr
hct
center
bydgoszcz
krakow
lublin
poznan
wroclaw
data
analyz
central
two
independ
research
data
first
period
collect
retrospect
prospect
afterward
viral
infect
classifi
episod
diagnos
basi
clinic
manifest
supplement
appropri
test
latent
requir
monitor
molecular
level
follow
latent
virus
includ
analysi
cmv
ebv
hsv
vzv
polyoma
bk
viru
bkv
episod
virus
includ
influenza
b
fluav
flubv
respect
communityacquir
respiratori
virus
carv
parainfluenza
hpiv
human
metapneumoviru
hmpv
respiratori
syncyti
viru
rsv
rhinoviru
rhv
well
parvoviru
hepatotrop
virus
adenoviru
adv
rotaviru
rv
noroviru
nov
detect
rv
nov
stool
perform
use
serolog
method
virus
polymeras
chain
reaction
pcr
base
analysi
use
diagnosi
viral
infect
materi
deriv
blood
urin
cerebrospin
fluid
respiratori
swab
bronchoalveolar
lavag
accord
recommend
european
confer
infect
leukaemia
ecil
preemptiv
quantit
approach
introduc
infect
cmv
ebv
allohct
patient
recurr
viral
infect
defin
new
episod
viral
infect
patient
previou
evid
viral
infect
viru
detect
least
week
activ
surveil
recurr
infect
could
result
reactiv
latent
viru
exogen
reinfect
multipl
viral
infect
defin
infect
two
virus
one
patient
time
studi
period
signific
plasma
cmvdnaemia
ebvdnaemia
defin
threshold
valu
copiesml
standard
uniform
prophylaxi
appli
patient
undergo
hct
commonli
accept
strategi
perform
prophylact
empir
target
antiinfecti
therapi
variou
agent
case
signific
cmvdnaemia
ebvdna
emia
andor
cmvor
ebvdiseas
specif
treatment
implement
event
defin
diagnosi
first
specif
infecti
disord
categor
variabl
compar
chisquar
test
noncategor
variabl
compar
mannwhitney
u
test
hazard
ratio
hr
confid
interv
ci
calcul
differ
occurr
infect
patient
cumul
incid
viral
infect
calcul
use
compet
risk
analysi
start
day
transplant
day
first
specif
infect
death
consid
compet
event
kaplanmei
method
use
determin
infectionrel
mortal
overal
surviv
logist
regress
method
use
multivari
analysi
report
pvalu
twosid
p
consid
statist
signific
analysi
period
consecut
month
total
hct
allohct
autohct
perform
indic
hct
acut
lymphoblast
leukemia
acut
myeloblast
leukemia
aml
neuroblastoma
primari
immunodefici
bone
marrow
failur
syndrom
nonhodgkin
lymphoma
hodgkin
lymphoma
nhlhd
ewe
sarcoma
myelodysplast
syndrom
indic
tabl
diagnos
allohct
primari
infect
recurr
infect
autohct
patient
supplementari
tabl
cumul
incid
viral
infect
allohct
patient
autohct
patient
p
figur
due
small
number
infect
autohct
set
data
exclud
analysi
present
supplementari
tabl
allohct
set
viral
infect
singl
pathogen
occur
patient
multipl
viral
infect
patient
two
virus
three
virus
four
virus
five
virus
cumul
incid
viral
infect
cmv
bkv
ebv
adv
rv
fluav
vzv
rsv
nov
hpiv
rhv
hsv
hmpv
hbv
incid
cmv
bkv
ebv
infect
significantli
higher
adv
p
viral
infect
cumul
incid
four
frequent
viral
infect
shown
figur
viral
infect
occur
within
first
month
allohct
differ
median
patient
age
median
time
allohct
specif
viral
infect
respect
valu
rang
month
case
vzv
hsv
nov
late
infect
observ
median
time
month
respect
supplementari
tabl
specif
viral
infect
primari
infect
recurr
infect
episod
therapi
perform
pharmacotherapi
symptomat
therapi
episod
vzv
hpiv
hsv
hmpv
infect
cmv
fluav
ebv
adv
bkv
infecti
episod
specif
antivir
pharmacotherapi
use
specif
pharmacotherapi
use
rv
rhv
nov
hbv
frequent
symptomat
therapi
use
rv
adv
bkv
infect
tabl
median
time
treatment
specif
viral
infect
rang
day
ebv
rv
fluav
rhv
nov
day
bkv
day
cmv
infect
supplementari
tabl
death
relat
rv
vzv
rsv
rhv
nov
hsv
hmpv
infect
episod
viral
infect
one
death
relat
fluav
surviv
one
hpiv
surviv
four
frequent
viral
infect
cmv
bkv
ebv
adv
surviv
rate
rang
adv
infect
ebv
infect
differ
specif
viral
infect
figur
respect
primari
diagnosi
surviv
viral
infect
aml
patient
statist
differ
two
figur
primari
diseas
multivari
analysi
risk
infect
higher
allohct
p
autohct
allohct
patient
risk
higher
acut
leukemia
patient
vs
p
mud
vs
msd
order
assess
impact
antivir
reactiv
ebvdnaemia
analyz
use
antivir
drug
within
day
onset
signific
ebvdnaemia
ebv
infecti
episod
case
infect
preced
anoth
viral
infect
includ
cmv
bkv
adv
rv
primari
caus
morbid
nonrelaps
mortal
follow
hct
acut
chronic
gvhd
organ
dysfunct
infect
chang
transplant
procedur
implement
effect
support
care
strategi
decreas
incid
infecti
complic
earli
condit
therapi
allohct
also
prolong
risk
beyond
day
late
infect
might
caus
type
microorgan
howev
risk
predict
surmount
use
tailor
prevent
strategi
articl
focus
viral
complic
children
hct
herein
report
result
multicent
nationwid
studi
epidemiolog
risk
factor
outcom
viral
infect
children
adolesc
hct
period
six
consecut
year
patient
treat
therapeut
protocol
use
compar
principl
support
therapi
shown
high
incid
viral
infect
allohct
patient
wherea
autohct
patient
incid
episod
compar
studi
disproport
result
allogen
sourc
stem
cell
tcell
deplet
select
moderatetosever
gvhd
use
immunosuppress
drug
especi
steroid
allohct
patient
observ
cmv
highest
incid
viral
infect
cmv
one
difficult
infect
occur
allohct
cmv
serostatu
donor
recipi
transplant
significantli
influenc
incid
cmv
recurr
wherea
immunosuppress
statu
recipi
import
factor
cmv
infect
monitor
sensit
techniqu
pcr
test
whole
blood
allow
intervent
develop
cmv
diseas
preemptiv
therapi
use
standalon
strategi
combin
antivir
prophylaxi
recent
letermovir
given
prophylaxi
shown
reduc
risk
clinic
signific
cmv
infect
shown
ganciclovir
foscarnet
frequent
use
drug
cohort
therapi
cmv
reactiv
accordingli
current
recommend
firstlin
preemptiv
treatment
nevertheless
manag
patient
resist
refractori
cmv
infect
cmv
diseas
challeng
combin
therapi
ganciclovir
foscarnet
cidofovir
leflunomid
artesun
consid
patient
resist
refractori
secondlin
thirdlin
antivir
drug
immunosuppress
alway
reduc
possibl
observ
cumul
incid
bkv
infect
surviv
rate
cesaro
et
al
report
bkvrelat
hemorrhag
cystiti
occur
pediatr
adult
recipi
undergo
allohct
specif
antibkv
prophylaxi
avail
fluoroquinolon
recommend
given
lack
signific
effect
bkv
replic
hemorrhag
cystiti
sever
select
antibiot
resist
studi
cidofovir
frequent
use
drug
treatment
bkv
infect
cidofovir
dose
mgkg
everi
week
probenecid
mgkg
timesweek
without
probenecid
use
author
treatment
bkv
hemorrhag
cystiti
although
without
strong
recommend
use
dose
clinic
manifest
adv
infect
immunocompet
host
includ
upper
respiratori
diseas
gastroenter
kerato
conjunct
selflimit
case
although
sever
manifest
includ
enceph
myocard
pneumonia
sporad
observ
immunocompromis
patient
adv
caus
system
diseas
lethal
organ
damag
prophylact
antivir
therapi
avail
antivir
drug
current
recommend
intraven
cidofovir
current
regard
standard
care
case
adv
diseas
children
frequent
affect
adv
adult
vs
respect
observ
incid
adv
infect
surviv
rate
rel
low
percentag
infect
carv
origin
observ
analysi
carv
respiratori
tract
infect
recogn
signific
caus
morbid
mortal
patient
leukemia
undergo
hct
late
frequenc
document
respiratori
viru
infect
among
allohct
among
autohct
howev
time
period
viral
antigen
detect
immunofluoresc
enzym
immunoassay
use
diagnost
last
decad
rapid
highli
sensit
molecular
test
develop
made
avail
recent
multiplex
pcr
platform
detect
multipl
viral
pathogen
choi
et
al
report
allohct
children
incid
rhv
infect
rsv
hpiv
hmpv
yet
half
infect
acquir
hospit
case
carv
infect
ribavirin
intraven
immunoglobulin
recommend
hmpv
hpiv
rsv
infect
insuffici
evid
specif
recommend
infect
caus
coronaviru
rhv
observ
rel
low
rate
influenza
infect
case
influenza
b
infect
may
due
environment
prophylaxi
annual
vaccin
patient
household
contact
hospit
prophylact
use
neuraminidas
inhibitor
influenza
season
case
current
guidelin
european
confer
infect
leukemia
recommend
diagnosi
base
pcr
materi
collect
respiratori
tract
especi
bronchoalveolar
lavag
neuraminidas
inhibitor
oral
oseltamivir
inhal
zanamivir
current
effect
therapeut
agent
influenza
rv
nov
import
pathogen
viral
gastroenter
children
observ
cumul
incid
rv
nov
treat
symptomat
therapi
death
observ
studi
incid
rv
infect
vari
adult
allohct
autohct
recipi
pediatr
allohct
recipi
pediatr
hct
incid
novassoci
gastroenter
report
novrel
mortal
pcr
well
viru
antigen
detect
stool
commonli
use
diagnosi
rv
nov
infect
specif
prophylaxi
rvand
novrel
gastroenterocol
avail
howev
oral
immunoglobulin
nitazoxanid
use
studi
immunocompet
individu
primari
ebv
infect
reactiv
induc
usual
asymptomat
infect
infecti
mononucleosi
immunocompromis
patient
ebv
reactiv
subclin
requir
therapi
howev
may
manifest
encephalitismyel
pneumonia
hepat
ebvassoci
tumor
ptld
transplant
recipi
develop
ebv
reactiv
incid
ebvptld
vari
accord
sourc
hematopoiet
cell
associ
cell
manipul
detail
immunosuppress
regimen
use
observ
high
incid
ebv
infect
allohct
patient
case
autohct
set
ebv
reactiv
rituximab
use
patient
surviv
infect
also
observ
almost
ebv
reactiv
episod
preced
viral
infect
treat
antivir
prevent
develop
signific
ebvdnaemia
need
rituximab
treatment
clinic
proven
evid
antivir
drug
prevent
ebv
reactiv
allohct
pediatr
patient
antivir
agent
ganciclovir
activ
ebv
presum
low
level
viral
thymidin
kinas
express
lytic
phase
lack
express
latenc
intraven
immunoglobulin
also
impact
ptld
neither
ganciclovirfoscarnet
cidofovir
therapyprophylaxi
impact
develop
ebvptld
antivir
agent
recommend
prospect
monitor
ebvdnaemia
recommend
patient
allohct
patient
close
monitor
symptom
andor
sign
attribut
ebv
infect
ptld
follow
preemptiv
therapi
recommend
highrisk
allohct
rituximab
mgm
weekli
reduct
immunosuppress
therapi
possibl
donor
ebvspecif
cytotox
tcell
ebvctl
infus
avail
compar
rituximab
adopt
cellular
immunotherapi
higher
respons
rate
fewer
relaps
found
allohct
acut
leukemia
acgvhd
mudmmudhct
risk
factor
viral
infect
cmv
donorrecipi
serostatu
era
transplant
mudhct
cgvhd
found
studi
risk
factor
viral
infect
also
found
cmvigg
seroposit
recipi
mud
mmudhct
risk
factor
death
viral
infect
children
hct
uniqu
observ
studi
avail
analyz
issu
incid
viral
infect
high
allohct
patient
autohct
patient
viral
infect
episod
frequent
viral
infect
allohct
cmv
bkv
ebv
viral
infect
occur
within
first
month
allohct
requir
pharmacotherapi
symptomat
therapi
median
time
treatment
specif
viral
infect
rang
ebv
day
cmv
highest
infectionrel
mortal
observ
case
cmv
infect
wherea
primari
diagnosi
influenc
surviv
viral
infect
risk
factor
viral
infect
allohct
acut
leukemia
acgvhd
mudmmud
vs
msd
risk
factor
death
viral
infect
cmvigg
seroposit
acut
lymphoblast
leukemia
recipi
mudmmud
vs
msd
incid
ebv
infect
requir
preemptiv
treatment
rituximab
allohsct
children
case
ebv
infect
episod
preced
viral
infect
treat
antivir
prevent
develop
signific
ebvdnaemia
need
rituximab
treatment
case
clinic
proven
evid
antivir
drug
prevent
ebv
reactiv
allohct
pediatr
patient
addit
case
gvhd
risk
factor
possibl
facilit
develop
signific
ebvdnaemia
antivir
therapi
infect
studi
conduct
accord
declar
helsinki
approv
ethic
committe
collegium
medicum
bydgoszcz
nicolau
copernicu
univers
torun
patient
data
analyz
anonym
neither
individu
data
publish
intervent
perform
patient
patient
consent
waiv
ethic
committe
acv
aciclovir
adv
adenoviru
acgvhd
acutechron
graft
versu
host
diseas
acut
lymphoblast
leukemia
allo
allogen
aml
acut
myeloblast
leukemia
anc
absolut
neutrophil
count
arac
cytarabin
auto
autolog
bcnu
carmustin
bkv
polyoma
bk
viru
bm
bone
marrow
carv
communityacquir
respiratori
viru
ci
confid
interv
cibmtr
center
intern
blood
marrow
transplant
research
cmv
cytomegaloviru
day
